IWR-1-endo

目录号:S7086 别名: endo-IWR 1, IWR-1

仅限科研使用

IWR-1-endo (endo-IWR 1, IWR-1)是一种Wnt通路抑制剂,在表达 Wnt3A 的 L-细胞中IC50为180 nM,诱导Axin2蛋白水平,并通过稳定Axin骨架破坏复合体来促进β-catenin磷酸化。

IWR-1-endo Chemical Structure

CAS: 1127442-82-3

规格 价格 库存 购买数量
10mM (1mL in DMSO) RMB 975.58 现货
RMB 900.38 现货
RMB 2050.64 现货
RMB 5151.51 现货
大包装 有超大折扣

今日订购,明日送达 全国免运费 分装免费 分装成小规格产品(单支最小为1mg)
如1支10mg产品可分装为10支1mg产品

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的IWR-1-endo发表文献86篇:

产品安全说明书

Wnt/beta-catenin抑制剂选择性比较

相关Wnt/beta-catenin产品

生物活性

产品描述 IWR-1-endo (endo-IWR 1, IWR-1)是一种Wnt通路抑制剂,在表达 Wnt3A 的 L-细胞中IC50为180 nM,诱导Axin2蛋白水平,并通过稳定Axin骨架破坏复合体来促进β-catenin磷酸化。
靶点
Wnt [1]
(L-cells expressing Wnt3A)
180 nM
体外研究

IWR-1 和XAV939作为Wnt通路的可逆抑制剂,在体内外具有相似的药理作用,IWR-1通过与Axin相互作用而发挥效果,而XAV939直接与TNKS结合。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BL21 (DE3) NGnnbpNHfW6ldHnvckBie3OjeR?= NX25TIxsQTBibXnudy=> MkLKRYN1cX[rdImgc4YhVi22ZYLtbY52eyCqZYjhTIl{NXSjZ3fl[EBpfW2jbjDUUnNMOiCneIDy[ZN{\WRiaX6gSZNkcGW{aXPobYEh[2:uaTDCUFIyKCiGRUOpJINmdGy|IIXzbY5oKGKrb4Tpcplt[XSnZDDORWQsKGG|IIP1ZpN1emG2ZTDh[pRmeiB7MDDtbY5{KGK7IGfld5Rmem5iYnzveEBidmGueYPpd{whTUN3MDC9JFAvOiEQvF2u NHXoUlA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkKzN|MzOCd-MkKyN|M{OjB:L3G+
SW480 M2nvSmZ2dmO2aX;uJIF{e2G7 MVuyOEBpenN? Mk\PTY5pcWKrdHnvckBw\iC2YX7rfZJie2ViaX6gbJVu[W5iU2e0PFAh[2WubIOgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIH;mJIF5cW5{IHHmeIVzKDJ2IHjyd{BjgSCKb3XjbJN1KGS7ZT3iZZNm\CCvZYToc4QtKEWFNUCgQUAzNjVizszNMi=> Mk\yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5MEG1NVcoRjJ|N{CxOVE4RC:jPh?=
HEK293T NVPRRVFWTnWwY4Tpc44h[XO|YYm= NFvTb5dKdmirYnn0bY9vKG:oIHLleIEu[2G|ZXnuMYRmeGWwZHXueEBk[W6xbnnjZYwhX262MzDwZZRpf2G7IHnuJIh2dWGwIFjFT|I6O1RiY3XscJMh[nlibIXjbYZmemG|ZTDy[ZBwenSncjDn[Y5mKGG|c3H5MEBKSzVyIE2gNE4xOjZizszNMi=> MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF7MUW1O{c,OjJzOUG1OVc9N2F-
SW480 NELIUXpHfW6ldHnvckBie3OjeR?= NUPvUYxyPDBidH:gOFghcHK| MlrPTY5pcWKrdHnvckBw\iC2YX7rfZJie2ViaX6gbJVu[W5iU2e0PFAh[2WubIOgZZN{\XO|ZXSgZZMh\GWpcnHkZZRqd25ib3[gZoV1[SClYYTlcolvKGGodHXyJFQxKHSxIES4JIhzeyxiSVO1NEA:KDBwMkWg{txONg>? MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzdyMUWxO{c,OjN5MEG1NVc9N2F-
L-Wnt-STF NVHjRoU6TnWwY4Tpc44h[XO|YYm= MX2yOEBpenN? NG[1U2ZKdmirYnn0bY9vKG:oIGTOT3MuOiCrbjDtc5V{\SCOLWfueE1UXEZiY3XscJMh[XO|ZYPz[YQh[XNiZHnzdpVxfGmxbjDv[kBYdnRic3nncoFtcW6pIHHmeIVzKDJ2IHjyd{BjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO|YYmsJGlEPTBiPTCwMlA2PiEQvF2u NEPkXlA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEWyO|c6Oid-MkS1Nlc4QTJ:L3G+
L-Wnt-STF MXjGeY5kfGmxbjDhd5NigQ>? NGj1XWozPCCqcoO= M3LmPGlvcGmkaYTpc44hd2ZiVF7LV{0yKGmwIH3veZNmKExvV370MXNVTiClZXzsd{Bie3Onc4Pl[EBieyCmaYPyeZB1cW:wIH;mJHdvfCC|aXfuZYxqdmdiYX\0[ZIhOjRiaILzJIJ6KGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeTygTWM2OCB;IECuNVMyKM7:TT6= MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV{N{e5Nkc,OjR3Mke3PVI9N2F-
HT29 NWPNNmxOTnWwY4Tpc44h[XO|YYm= M3fD[VI1KGi{cx?= MYPJcohq[mm2aX;uJI9nKFewdDDzbYdv[WyrbnegbY4hcHWvYX6gTHQzQSClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJIJmfGFvY3H0[Y5qdi2vZXTpZZRm\CCWY3[vUIVnKHS{YX7zZ5JqeHSrb37hcEBi[3Srdnn0fUBi\nSncjCyOEBpenNiYomg[JVidCCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO|YYmgdoVt[XSrdnWgeI8h[2:wdILvcEwhUUN3MDC9JFI1NjRizszNMi=> MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl3MES4PUc,OjR7NUC0PFk9N2F-
DLD1 NULLcmhwTnWwY4Tpc44h[XO|YYm= NYiwdXltOTBidV2= M1Thbmlv\HWldHnvckBw\iCDeHnuNkBqdiCqdX3hckBFVERzIHPlcIx{KG:4ZYLlfJBz\XO|aX7nJGlYWi2LUzDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCZboSgdIF1cHejeTDhZ5Rqfmm2eTDheEAyOCC3TTDifUBUXEZicnXwc5J1\XJiYYPzZZkhdWW2aH;k NELYO4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUGyOVE2Pid-MUmxNlUyPTZ:L3G+
HEK293 MYjGeY5kfGmxbjDhd5NigQ>? NVXLNZQyTGm|cHzhZ4Vu\W62IH;mJGlYWi2SQjDmdo9uKEG6aX6yJIlvKEiHS{K5N{Bk\WyuczDifUBY\XO2ZYLuJIJtd3RibXX0bI9l Mmq0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlzMkWxOVYoRjF7MUK1NVU3RC:jPh?=
DLD1 NIHOV2lHfW6ldHnvckBie3OjeR?= M2HHTGlvcGmkaYTpc44hd2ZiQYjpclIheHKxdHXpckBl\We{YXTheIlwdiCrbjDoeY1idiCGTFSxJINmdGy|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>? NGTYclI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUGyOVE2Pid-MUmxNlUyPTZ:L3G+
DLD1 NXjEfJdkTnWwY4Tpc44h[XO|YYm= NE\zS3BKdmS3Y4Tpc44hd2ZiQYjpclIh[WOldX31cIF1cW:wIHnuJIh2dWGwIFTMSFEh[2WubIOgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5iVHjyOFEheGixc4Doc5J6dGG2ZXSgZoV1[S2lYYPlbY4hdGW4ZXzzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?= MlrYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlzMkWxOVYoRjF7MUK1NVU3RC:jPh?=
DLD1 M4[5eWZ2dmO2aX;uJIF{e2G7 M2HR[mlv\HWldHnvckBw\iCDeHnuNkBi[2O3bYXsZZRqd25iaX6gbJVu[W5iRFzENUBk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCVZYKzO{BxcG:|cHjvdplt[XSnZDDi[ZRiNWOjc3XpckBt\X[nbIOgZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| NHrVXHA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUGyOVE2Pid-MUmxNlUyPTZ:L3G+
DLD1 NEnxZmZHfW6ldHnvckBie3OjeR?= NUfHUZNCTGWlcnXhd4UhcW5iYnX0ZU1k[XOnaX6gZYNkfW23bHH0bY9vKGmwIHj1cYFvKESOREGgZ4VtdHNiZYjwdoV{e2mwZzDpckBCWENibYX0ZY51 NFjBbmU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUGyOVE2Pid-MUmxNlUyPTZ:L3G+
DLD1 M3LKb2Z2dmO2aX;uJIF{e2G7 NWG1eVduOiCqcoO= NXHkWVZ{UW6mdXP0bY9vKG:oIFH4bY4zKHO2YXLpcIl7[XSrb36gbY4hcHWvYX6gSGxFOSClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\WRidILhcpNkemmydHnvckBw\iCDeHnuNkBi\nSncjCyJIhzeyCkeTDSWE1RS1JibXX0bI9l M{C1ZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MUK1NVU3Lz5zOUGyOVE2PjxxYU6=
DLD1 MknmSpVv[3Srb36gZZN{[Xl? MV3JcoR2[3Srb36gc4YhSXirbkKgZYNkfW23bHH0bY9vKGmwIHj1cYFvKESOREGgZ4VtdHNiYYPz[ZN{\WRiYYOg[IVkemWjc3WgbY4h\nKnZTDi[ZRiNWOjc3XpckBt\X[nbIOgZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| NHS5W5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUGyOVE2Pid-MUmxNlUyPTZ:L3G+
DLD1 MVnGeY5kfGmxbjDhd5NigQ>? MXPJcoR2[3Srb36gc4YhSXirbkKgd5Ri[mmuaYrheIlwdiCrbjDoeY1idiCGTFSxJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiV370M4JmfGFvY3Hz[YlvKHCjdHj3ZZk> M4PURlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MUK1NVU3Lz5zOUGyOVE2PjxxYU6=
DLD1 NUHGeGVoTnWwY4Tpc44h[XO|YYm= MnnjTY5lfWO2aX;uJI9nKEG6aX6yJIFk[3WvdXzheIlwdiCrbjDoeY1idiCGTFSxJINmdGy|IHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKFOnckOzJJBpd3OyaH;yfYxifGWmIHLleIEu[2G|ZXnuJIxmfmWuczDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN? NVXCZWU5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmxNlUyPTZpPkG5NVI2OTV4PD;hQi=>
DLD1 MXfGeY5kfGmxbjDhd5NigQ>? M4HyfWlv\HWldHnvckBw\iCDeHnuNkBi[2O3bYXsZZRqd25iaX6gbJVu[W5iRFzENUBk\WyuczDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN? NHiwNWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUGyOVE2Pid-MUmxNlUyPTZ:L3G+
DLD1 NYjaRmh{TnWwY4Tpc44h[XO|YYm= MWGxJJRwKDJyIIXN M{npelI1KGi{cx?= NEe2VGRKdmirYnn0bY9vKG:oIIThcot6emG|ZTDpckBpfW2jbjDEUGQyKGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gWGNHNWSncHXu[IVvfCC2cnHud4NzcXC2aX;uZYwh[WO2aY\peJkh[XRiMTD0c{AzOCC3TTDh[pRmeiB{NDDodpMh[nliZIXhcEBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[Xl? MoPzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3Mke3PVIoRjJ2NUK3O|kzRC:jPh?=
DLD1 NXnuOXI1S3m2b4TvfIlkcXS7IHHzd4F6 NHvTSI4yKHSxIEKwJJVO MlvNNVAh\GG7cx?= M3f0UWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGRNTDFiY3XscJMh[XO|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYYSgNUB1dyB{MDD1UUBu\WG|dYLl[EBwdiCmYYmgNVAh[nliY4L5d5RidCC4aX;s[ZQhe3SjaX7pcoc> M3PzT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUK3O|kzLz5{NEWyO|c6OjxxYU6=
HT29 M32zV2Z2dmO2aX;uJIF{e2G7 NEnCToQzPSC3TR?= NXi3SppTOjRiaILz M3TiSmlvcGmkaYTpc44hd2ZiV370JJNq\26jbHnu[{BqdiCqdX3hckBJXDJ7IHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4Yh[mW2YT3jZZRmdmmwLX3l[IlifGWmIGTj[k9N\WZidILhcpNkemmydHnvcoFtKGGldHn2bZR6KGG2IEK1JJVOKGGodHXyJFI1KGi{czDifUBlfWGuIHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUBz\WyjdHn2[UB1dyClb370do9t MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl3MES4PUc,OjR7NUC0PFk9N2F-
HT29 M1XTbmZ2dmO2aX;uJIF{e2G7 MVOyOUB2VQ>? MnvWNlQhcHK| NGXYO3NKdmirYnn0bY9vKG:oIGfueEB{cWewYXzpcochcW5iaIXtZY4hUFR{OTDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGKndHGtZ4F1\W6rbj3t[YRq[XSnZDDUZ4YwVGWoIITyZY5{[3KrcITpc45idCCjY4Tpeol1gSCjdDCyOUB2VSCjZoTldkAzPCCqcoOgZpkh\HWjbDDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZkhemWuYYTpeoUhfG9iY3;ueJJwdCCrbjDwdoV{\W6lZTDv[kBIW0tvM3LleIEhcW6qaXLpeI9zKEyrQ3y= NWrIeVRNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OVA1QDlpPkK0PVUxPDh7PD;hQi=>
HT29 NXrQTIt2TnWwY4Tpc44h[XO|YYm= MoLQNlUhfU1? MV:yOEBpenN? M1nRXWlvcGmkaYTpc44hd2ZiV370M4JmfGFvY3H0[Y5qdiC|aXfuZYxqdmdiaX6gbJVu[W5iSGSyPUBk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCjeHnuNkBuWk6DIHX4dJJme3Orb36gZZQhOjVidV2gZYZ1\XJiMkSgbJJ{KGK7IIH1ZY51cXSjdHn2[UBz\WGuLYTpcYUhWEOUIHHzd4F6 NF7FRVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm1NFQ5QSd-MkS5OVA1QDl:L3G+
Assay
Methods Test Index PMID
Western blot E-cadherin / N-cadherin / Snail / Vimentin p-Akt / Akt Survivin 26450645

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

溶解度(25°C)

体外

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 409.44
化学式

C25H19N3O3

CAS号 1127442-82-3
储存条件 3年 -20°C 粉状
2年 -80°C 溶于溶剂

动物体内配方计算器(澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)

mg/kg g μL

第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)

% DMSO % % Tween 80 % ddH2O
%DMSO %

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于μL DMSO溶液(母液浓度mg/mL,:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);

体内配方配制方法:μL DMSO母液,加入μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入μL ddH2O,混匀澄清。

体内配方配制方法:μL DMSO母液,加入μL Corn oil,混匀澄清。

注意:1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

摩尔浓度计算器

质量 浓度 体积 分子量

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

* 必填项

请输入您的姓名
请输入您的邮箱地址 请输入一个有效的邮箱地址
请写点东西给我们
Tags: buy IWR-1-endo | IWR-1-endo supplier | purchase IWR-1-endo | IWR-1-endo cost | IWR-1-endo manufacturer | order IWR-1-endo | IWR-1-endo distributor